6625-94-1|2,4,7-Trichloroquinazoline| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 6625-94-1 ] Purity: 98% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 6625-94-1 ]

CAS No. :	6625-94-1
Formula :	C₈H₃Cl₃N₂
M.W :	233.48
SMILES Code :	ClC1=CC2=NC(Cl)=NC(Cl)=C2C=C1
MDL No. :	MFCD09954887
InChI Key :	MFVNIGBXSLGABC-UHFFFAOYSA-N
Pubchem ID :	246037

Safety of [ 6625-94-1 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Application In Synthesis of [ 6625-94-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 6625-94-1 ]

[ 6625-94-1 ] Synthesis Path-Downstream 1~35

1
[ 13165-35-0 ]
[ 6625-94-1 ]

Yield	Reaction Conditions	Operation in experiment
89%	With N-ethyl-N,N-diisopropylamine; trichlorophosphate; In acetonitrile; for 36h;Reflux;	Step B: Preparation of 2,4,7-trichloroquinazoline. A mixture of 7-chloro-1H-quinazoline-2,4-dione (2.0 g, 10 mmol) was suspended in ACN (50 mL), then POCl3 (5.0 mL, 55 mmol) was added. This was followed by addition of DIEA (5.0 mL, 28 mmol). The resulting mixture was heated to reflux for 36 h, and then allowed to cool to rt and concentrated. The residue was carefully treated with ice and sodium bicarbonate. The resulting solid was collected by filtration and dried. Chromatographic purification (EtOAc/hexanes 0:100 to 10:90) provided the titled compound (2.1 g, 89%). The MS and NMR data are in agreement with those that have been previously described: Bioorganic & Medicinal Chemistry, 2003, 11, 2439-2444. 1H NMR (400 MHz, DMSO-d6): 8.32 (d, J=8.7 Hz, 1H), 8.20 (d, J=1.9 Hz, 1H), 7.93 (dd, J=9.0, 2.1 Hz, 1H).
	In ice-water; trichlorophosphate;	b) 10.5 g (0.053 mol) of 7-chloro-1,2,3,4-tetrahydro-quinazoline-2,4-dione were suspended in 35 ml (0.48 mol) of phosphorus oxychloride and heated to 120 C. for 24 hrs. The reaction mixture was left to cool to room temperature and poured on to ice-water. The brown precipitate was filtered off under suction, dried and chromatographed over silica gel with methylene chloride as the eluent. There were obtained: 7.2 g (58%) of 2,4,7-trichloroquinazoline as yellow crystals; MS: me/e=232, 234 (M+).
3.88 g	With N-ethyl-N,N-diisopropylamine; trichlorophosphate; for 4h;Reflux;	<Step 2> 2,4,7-trichloroquinazoline Diisopropylethylamine (9.21 ml, 52.9 mmol) was added to a mixture of 7-chloroquinazoline-2,4(1H,3H)-dione (5.2 g, 26.5 mmol) prepared in Step 1 and phosphorus oxychloride (26 ml), and they were stirred at reflux for 4 hours. After cooling the reaction mixture to room temperature, the same was added into ice water, and basified to pH 7-8 by using sodium bicarbonate. The aqueous layer was extracted with dichloromethane, and the organic layer was dried on anhydrous magnesium sulfate and concentrated under reduced pressure. The resulting residue was purified with silica gel column chromatography (dichloromethane) to give the titled compound (3.88 g) as a white solid. 1H NMR (400 MHz, CDCl3) delta 8.22 (d, 1H), 8.01 (s, 1H), 7.68 (d, 1H).

References: [1]Pharmaceutical Chemistry Journal,1987,vol. 21,p. 478 - 483.
Khimiko-Farmatsevticheskii Zhurnal,1987,vol. 21,p. 802 - 807.
[2]Journal of Medicinal Chemistry,2008,vol. 51,p. 7855 - 7865.
[3]Journal of Medicinal Chemistry,2016,vol. 59,p. 7268 - 7274.
[4]Patent: US2010/204226,2010,A1 .Location in patent: Page/Page column 22.
[5]Bioorganic and Medicinal Chemistry,2003,vol. 11,p. 2439 - 2444.
[6]Patent: DE931845,1952, .
[7]Journal of the Chemical Society,1948,p. 1759,1765.
[8]Journal of Medicinal Chemistry,2007,vol. 50,p. 2297 - 2300.
[9]Patent: US5688803,1997,A .
[10]Journal of Medicinal Chemistry,2011,vol. 54,p. 6028 - 6039.
[11]Journal of Medicinal Chemistry,2014,vol. 57,p. 3075 - 3093.
[12]Journal of Medicinal Chemistry,2014,vol. 57,p. 5141 - 5156.
[13]Patent: US2016/90374,2016,A1 .Location in patent: Paragraph 0182; 0183.

2
[ 6789-94-2 ]
[ 6625-94-1 ]
[ 76004-40-5 ]

References: [1]Journal of Medicinal Chemistry,1981,vol. 24,p. 127 - 140.

3
[ 6625-94-1 ]
[ 60-34-4 ]
[ 129302-30-3 ]

References: [1]Journal of Heterocyclic Chemistry,1990,vol. 27,p. 723 - 726.

4
[ 6625-94-1 ]
[ 111218-91-8 ]

References: [1]Pharmaceutical Chemistry Journal,1987,vol. 21,p. 478 - 483.
Khimiko-Farmatsevticheskii Zhurnal,1987,vol. 21,p. 802 - 807.

5
[ 951004-04-9 ]
[ 6625-94-1 ]
(2,7-dichloro-quinazolin-4-yl)-[1-(3-ethoxy-4-methoxy-benzyl)-piperidin-4-yl]-amine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
3%	In N,N-dimethyl acetamide; at 200℃; for 0.5h;Microwave irradiation;	Step 2 (Method F):; A solution of <strong>[6625-94-1]2,4,7-trichloro-quinazoline</strong> (35.0 mg, 0.15 mmol, 1.0 equiv) and 1-(3-ethoxy-4-methoxy-benzyl)-piperidin-4-ylamine (47.6 mg, 0.18 mmol, 1.2 equiv; intermediate Al) in DMAc (2 mL) was heated by microwave irradiation to 200 0C for 30 min. Removal of the solvent under reduced pressure and purification by preparative HPLC on reversed phase eluting with a gradient of acetonitrile/water provided 1.8 mg (3%) of the title compound. MS (ISP): 461.3 [M+H]+.

References: [1]Patent: WO2008/692,2008,A2 .Location in patent: Page/Page column 49.

6
[ 6625-94-1 ]
[ 769158-10-3 ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 2297 - 2300.

7
[ 6625-94-1 ]
C₂₁H₂₀ClN₅O [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 2297 - 2300.

8
[ 6625-94-1 ]
7-chloro-2-pyrrolidin-1-yl-3<i>H</i>-quinazolin-4-one [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry,2003,vol. 11,p. 2439 - 2444.

9
[ 6625-94-1 ]
7-chloro-2-piperidin-1-yl-3<i>H</i>-quinazolin-4-one [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry,2003,vol. 11,p. 2439 - 2444.

10
[ 6625-94-1 ]
7-chloro-2-piperazin-1-yl-3H-quinazolin-4-one hydrochloride [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry,2003,vol. 11,p. 2439 - 2444.

11
[ 6625-94-1 ]
[ 187942-13-8 ]